This research study is evaluating a drug called tivozanib as a possible treatment for
ovarian, fallopian tube or primary peritoneal cancer.
Angiogenesis is the formation of new blood vessels. Tumors need blood vessels to grow and
spread. Tivozanib is an anti-angiogenesis medicine that fights cancer by cutting off a
tumor's blood supply so that it does not get the blood and nutrients it needs to grow.
In this research study, the Investigators are looking to see whether tivozanib works as a
maintenance therapy for ovarian, fallopian tube or primary peritoneal carcinoma in
participants who have achieved a complete response following chemotherapy. Maintenance
therapy is given after a disease has responded to previous treatment. It is given to help
prevent the spread or recurrence of the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
AVEO Pharmaceuticals, Inc. National Comprehensive Cancer Network